MNMD
Mind Medicine (MindMed) Inc. [MNMD] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
MNMD Stock Summary
Top 10 Correlated ETFs
MNMD
Top 10 Correlated Stocks
MNMD
In the News
MNMD Financial details
Company Rating
-
Market Cap
681.74M
Income
-98.4M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
57
Optionable
No
Shortable
Yes
Earnings
02 May 2024
P/E
-2.44
Forward P/E
-
PEG
-0.38
P/S
-
P/B
1.79
P/C
-
P/FCF
-4.47
Quick Ratio
3.78
Current Ratio
3.85
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-2.52
EPS next Y
-
EPS next Q
-
EPS this Y
59.48%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
31.11%
-
-
-
-
SMA20
24.96%
SMA50
34.2%
SMA100
94.01%
Inst Own
-
Inst Trans
-
ROA
-50%
ROE
-58%
ROC
-0.8%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
2.41-12.22
52W High
+74.83%
52W Low
+949%
RSI
49.53
Rel Volume
0.91
Avg Volume
2.2M
Volume
2.01M
Perf Week
-6.59%
Perf Month
16.17%
Perf Quarter
47.75%
Perf Half Y
62.51%
-
-
-
-
Beta
2.531
-
-
Volatility
0.84%, 2%
Prev Close
-6.67%
Price
20.98
Change
-9.8%
Something similar
Company Profile
- Volume Average 2.2M
- Market Capitalization 681.74M
- Employee 57
- CEO Mr. Robert Barrow
- Headquarters Vancouver,BC,CA
- IPO Date 2016-11-15
-
Website
https://www.mindmed.co 
Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.
